Drug Discovery Today

Article	Citations
Transitioning biomedical research toward human-centric methodologies: systems-based strategies	199
A new approach to treat type 2 diabetes – Targeting a non-insulin dependent pathway	189
Molecular biomarkers of glial activation and injury in epilepsy	180
Contents page	168
Artificial intelligence (AI) and alternative variables (AV) in drug discovery: A promising alliance	128
The epigenetic impact of fatty acids as DNA methylation modulators	126
Polysaccharides as therapeutic vehicles in pancreatic cancer	122
Contents page	109
Therapies for Inherited Retinal Dystrophies: What is Enough?	108
Trends in small molecule drug properties: A developability molecule assessment perspective	107
Nanofibers as drug-delivery systems for antimicrobial peptides	98
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	97
The recent progress of deep-learning-based in silico prediction of drug combination	96
Strengthening Molecular Glues: Design Strategies for Improving Thalidomide Analogs as Cereblon Effectors and Anticancer Agents	96
The ethics of animal research and testing: A US perspective	95
Contents page	93
Neoteric solvents for the pharmaceutical industry: an update	89
A personalized pharmaco-epistatic network model of precision medicine	86
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	85
Corrigendum to “A review of in vitro and in vivo methods and their correlations to assess mouthfeel of solid oral dosage forms” [Drug Discov. Today 26(3) (2021) 740–753]	81
Contents page 2	79
Fiduciary responsibility	79
Contents page 2	78
Crystallographic landscape provides molecular insights into the modes of action of diverse ROR-γt modulators	75
Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get?	75

Drug discovery for epigenetics targets	74
Contents page 1	71
Generic dry powder inhalers bioequivalence: Batch–to-batch variability insights	71
Trends, challenges, and success factors in pharmaceutical portfolio management: Cognitive biases in decision-making and their mitigating measures	71
Industry perspective on the nonclinical safety assessment of heterobifunctional degraders	69
Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)	67
The promise of crowdfunding to finance R&D of novel diagnostics and therapeutics for incurable diseases	67
Advancements in small molecule drug design: A structural perspective	66
Neurotrophin-targeted therapeutics: A gateway to cognition and more?	65
Antibody–drug conjugates: What drives their progress?	64
Improving the ability of antimicrobial susceptibility tests to predict clinical outcome accurately: Adding metabolic evasion to the equation	64
Contents page	63
Four scenarios for the future of medicines and social policy in 2030	63
An exploration of alternative therapeutic targets for aortic disease in Marfan syndrome	63
How can we unleash the potential of external controls in clinical trials?	62
Contents page	61
Innovation in breakthrough drugs and vaccines: Development risk, patient impact, and value	60
A pleiotropic–epistatic entangelement model of drug response	60
Fighting AMR with Host Immune Response Technology	60
The potential value of 5-androstenediol in countering acute radiation syndrome	59
Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy	58
Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners	58
Graph neural networks for automated de novo drug design	57
Integrating heterogeneous data to facilitate COVID-19 drug repurposing	55
Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights	55
Therapeutic potential of glutaminyl cyclases: Current status and emerging trends	54
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	54
Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?	54
Natural products in pursuing novel therapies of nonalcoholic fatty liver disease and steatohepatitis	53
Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2	53
Key considerations in formulation development for gene therapy products	52
Novel therapeutic strategies for autoimmune and inflammatory rheumatic diseases	51
Recent trends in interorganizational deal networks in pharmaceutical and biotechnology industries	51
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	51
Role of innovation in pharmaceutical regulation: A proposal for principles to evaluate EU General Pharmaceutical Legislation from the innovator perspective	50
Antitoxin nanoparticles: design considerations, functional mechanisms, and applications in toxin neutralization	50
Forty years of combinatorial technology	48
Ebola outbreaks: A stress test of the preparedness of medicines regulatory systems for public health crises	48
Data standards in drug discovery: A long way to go	47
The transmembrane domains of GPCR dimers as targets for drug development	47
The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	46
Pharma innovation: how evolutionary economics is shaping the future of pharma R&D	46
Targeting histone deacetylases: Emerging applications beyond cancer	45
Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy	45
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	44
Long-term follow-up after authorization of gene therapy: leveraging real-world data	43
Increased contribution of small companies to late-entry drugs: a changing trend in FDA-approved drugs during the 2020s	43
Academic drug discovery in an age of research abundance, and the curious case of chemical screens toward drug repositioning	43
Unlocking the potential of flavonoid-based co-crystal and co-amorphous systems	43
Drug repurposing: Known knowns to unknown unknowns – Network analysis of the repurposome	43

Toward the institutionalization of quantum computing in pharmaceutical research	42
New trends for osteoarthritis: Biomaterials, models and modeling	42
Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases	42
New Generation Anti-Obesity Pharmacotherapy: Companion or Competitor to Metabolic bariatric Surgery?	42
Impact of fenofibrate on NAFLD/NASH: A genetic perspective	42
Application of proteomics for novel drug discovery and risk prediction optimisation in stroke and myocardial infarction: a review of in-human studies	42
The hallmarks of tissue-agnostic therapies and strategies for early anticancer drug discovery	41
PROTACting the kinome with covalent warheads	40
Expression, regulation, and function of PD-L1 on non-tumor cells in the tumor microenvironment	40
Redefining what it means to age – the impact to society and pharmaceutical industry	40
Role of transcription termination factor Rho in anti-tuberculosis drug discovery	40
Peptides as innovative strategies to combat drug resistance in cancer therapy	40
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	39
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	39
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	39
CIPDB: A biological structure databank for studying cation and π interactions	39
Immunoconjugates and bispecific antibodies: Trends in therapeutic success and commercial focus	39
Targeting the endocannabinoid system: Structural determinants and molecular mechanism of allosteric modulation	38
Peptide modulators of cell migration: Overview, applications and future development	38
Polycystic ovary syndrome: Current scenario and future insights	38
Models and approaches to comprehend and address glial inflammation following spinal cord injury	38
Learning from COVID-19: How drug hunters can prepare for the next pandemic	38
Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities	37
Best practices for machine learning in antibody discovery and development	37
Overview of the Knowledge Management Center for Illuminating the Druggable Genome	37
Innovative strategies for measuring kinase activity to accelerate the next wave of novel kinase inhibitors	37
Recent trends in targeted delivery of smart nanocarrier-based microbial enzymes for therapeutic applications	37
Antibody–drug conjugates: prospects for the next generation	37
Three-dimensional cell culture: Future scope in cancer vaccine development	36
Beyond CL and VSS: A comprehensive approach to human pharmacokinetic predictions	36
The identification of essential cellular genes is critical for validating drug targets	36
Construction of cancer-on-a-chip for drug screening	35
Recent development in the design of small ‘drug-like’ and nanoscale glycomimetics against Escherichia coli infections	35
New views on endothelial dysfunction in gestational hypertension and potential therapy targets	35
Sodium ion channels as potential therapeutic targets for cancer metastasis	35
Advanced nanodelivery platforms for topical ophthalmic drug delivery	35
Petite miracles: insight into the nano-management of scarless wound healing	35
Mitochondrial dysfunction: A potential target for Alzheimer’s disease intervention and treatment	35
Can preclinical drug development help to predict adverse events in clinical trials?	34
Web resources facilitate drug discovery in treatment of COVID-19	34
Identification of biological targets through the correlation between cell line chemosensitivity and protein expression pattern	34
Which factors matter the most? Revisiting and dissecting antibody therapeutic doses	34
Sunitinib and its effect in the cardiovascular system	34
Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors	34
Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective	33
Structural basis of HIV inhibition by L-nucleosides: Opportunities for drug development and repurposing	33
Calming the cytokine storm of COVID-19 through inhibition of JAK2/STAT3 signaling	33
Experimental murine models of brainstem gliomas	33
Artificial intelligence and the future of life sciences	33
Specificity of pharmacokinetic modeling of nanomedicines	33
Current clinical trials for epigenetic targets and therapeutic inhibitors for pancreatic cancer therapy	33
Repurposing drugs as COVID-19 therapies: A toxicity evaluation	32
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	32
Patents, trade secrets and pricing	32
How doppelgänger effects in biomedical data confound machine learning	32
Current and future approaches for in vitro hit discovery in diabetes mellitus	32
General aspects of powder rheology applied to pharmaceutical formulations	31
Emergent treatments for β-thalassemia and orphan drug legislations	31
Formulation strategies for the development of high drug-loaded amorphous solid dispersions	31
Prioritizing quantum computing use cases in the drug discovery and development pipeline	31
Drugging the ‘undruggable’. Therapeutic targeting of protein–DNA interactions with the use of computer-aided drug discovery methods	31
Which cryptic sites are feasible drug targets?	31
The Value in Failure	31
R&D efficiency of leading pharmaceutical companies – A 20-year analysis	31
Restoring the epigenome in Alzheimer's disease: advancing HDAC inhibitors as therapeutic agents	31
MAT2A inhibition combats metabolic and transcriptional reprogramming in cancer	31
Best practices for artificial intelligence in life sciences research	30
Ferroptosis as a potential therapeutic target for age-related macular degeneration	30
Drug repurposing: An effective strategy to accelerate contemporary drug discovery	30
Concepts and applications of chemical fingerprint for hit and lead screening	30
Small molecules and their impact in drug discovery: A perspective on the occasion of the 125th anniversary of the Bayer Chemical Research Laboratory	30
Active pharmaceutical ingredients (APIs) in ionic liquids: An effective approach for API physiochemical parameter optimization	30
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	30
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	30
Emerging role of oncolytic viruses and stem cells in gene therapy: Should they be integrated?	30
Best practices for managing and disseminating resources and outreach and evaluating the impact of the IDG Consortium	30
Transfer learning empowers accurate pharmacokinetics prediction of small samples	30
Molecule-rich solutions for achieving novel non-opioid analgesics	29
CRISPR/Cas9 in the era of nanomedicine and synthetic biology	29
Benefits of hybrid QM/MM over traditional classical mechanics in pharmaceutical systems	29

Multiorgan locked-state model of chronic diseases and systems pharmacology opportunities	29
Modulation of serine/threonine-protein phosphatase 1 (PP1) complexes: A promising approach in cancer treatment	29
Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants	29
Machine Learning guided early drug discovery of small molecules	29
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	29
Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma	29
Revisiting the GBB reaction and redefining its relevance in medicinal chemistry: A review	29
ATP-binding cassette efflux transporters and MDR in cancer	29
Selenium as an emerging versatile player in heterocycles and natural products modification	28
3D printing of biologics—what has been accomplished to date?	28
Deep learning methods for molecular representation and property prediction	28
Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity	28
Synthesis and modification of bio-derived antibacterial Ag and ZnO nanoparticles by plants, fungi, and bacteria	28
Oral peptide delivery: challenges and the way ahead	28
Stimuli-sensitive drug delivery systems for site-specific antibiotic release	28
Novel and investigational therapies for wet and dry age-related macular degeneration	28
Recent advances in dual-ligand targeted nanocarriers for cancer therapy	28
Computational modeling approaches and regulatory pathways for drug combinations	27
Causal inference in drug discovery and development	27
Healthcare decision-making for tumour-agnostic therapies in Europe: lessons learned	27
The current status of COVID-19 vaccines. A scoping review	27
PHLPPs: Emerging players in metabolic disorders	27
Repurposing antidepressants for anticancer drug discovery	27
How successful are AI-discovered drugs in clinical trials? A first analysis and emerging lessons	27
Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors	26
Tubulin targeting agents and their implications in non-cancer disease management	26
Optical tweezers for drug discovery	26
Stromal disruption facilitating invasion of a ‘nano-arsenal’ into the solid tumor	26
Prospects of halofuginone as an antiprotozoal drug scaffold	26
Bioresponsive drug delivery systems	26
COVID-19 and fibrosis: Mechanisms, clinical relevance, and future perspectives	26
Drug repurposing for stroke intervention	26
Nicotinamide N-methyl transferase (NNMT): An emerging therapeutic target	25
Recent trends in STING modulators: Structures, mechanisms, and therapeutic potential	25
Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders	25
Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics	25
Unveiling the potential of molecular imprinting polymer-based composites in the discovery of advanced drug delivery carriers	25
Gastroretentive drug delivery systems: A holy grail in oral delivery	25
Native mass spectrometry-directed drug discovery: Recent advances in investigating protein function and modulation	25
Inflammation, stress and depression: An exploration of ketamine’s therapeutic profile	25
Bio-inspired nanomaterials as novel options for the treatment of cardiovascular disease	25
Obesity and insulin resistance: Pathophysiology and treatment	25
AlphaFold, allosteric, and orthosteric drug discovery: Ways forward	25
Targeting Ca2+ signaling: A new arsenal against cancer	24
The forced swim test has poor accuracy for identifying novel antidepressants	24
Applications of density functional theory in COVID-19 drug modeling	24
Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity	24
Progress in oral insulin delivery by PLGA nanoparticles for the management of diabetes	24
Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids	24
Contents page	24
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	24
ViralVacDB: A manually curated repository of viral vaccines	24
Manifold medicine: A schema that expands treatment dimensionality	24
Electron diffraction: Accelerating drug development	24
Small biotechs versus large pharma: Who drives first-in-class innovation in oncology?	24
Nanozyme-based synergistic therapeutic strategies against tumors	23
Contents page 1	23
Clinical research with targeted drugs in paediatric oncology	23
Towards Pharma 4.0 in clinical trials: A future-orientated perspective	23
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	23
Converging global crises are forcing the rapid adoption of disruptive changes in drug discovery	23
Contents page 2	23
AI for drug discovery is advancing rapidly: We need smart biology for it to fulfill its mission	23
Computational approaches for the identification of novel metal-binding pharmacophores: advances and challenges	23
Recent advancements in colchicine derivatives: Exploring synthesis, activities, and nanoformulations for enhanced therapeutic efficacy	23
Micro- and nanoformulations of paclitaxel based on micelles, liposomes, cubosomes, and lipid nanoparticles: Recent advances and challenges	23
Contents page 2	23
Molecular approaches for the treatment and prevention of Friedreich's ataxia	23
How missing value imputation is confounded with batch effects and what you can do about it	22
Contents page 2	22
Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases	22
Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation	22
Recent advances towards overcoming the blood–brain barrier	22
Contents page	22
Targeting neuroinflammation in distal symmetrical polyneuropathy in diabetes	22
SETDB1, an H3K9-specific methyltransferase: An attractive epigenetic target to combat cancer	22
Corrigendum to “An industrial approach towards solid dosage development for first-in-human studies: Application of predictive science and lean principles” [Drug Discov. Today 25 (2020) 505–518]	22
Medicinal mushrooms: Clinical perspective and challenges	22
Albendazole-induced liver injury in children: a cause for concern?	22
Steps toward nebulization in-use studies to understand the stability of new biological entities	22
Microfluidics for personalized drug delivery	22
Benchmarking the mechanisms of frequent hitters: limitation of PAINS alerts	22
Clinical strategies with antibody–drug conjugates as potential modifications for virotherapy	22
Point-of-care diagnostics approaches for detection of lung cancer-associated circulating miRNAs	21
AI in drug discovery: A wake-up call	21
Contents page	21
Cancer vaccines: An unkept promise?	21
Developing inhaled drugs for respiratory diseases: A medicinal chemistry perspective	21
Illuminating the druggable genome: Pathways to progress	21
Biofilm control by ionic liquids	21
Regulatory density as a means to refine current regulatory approaches for increasingly complex medicines	21
Integrated nanomaterials for non-invasive photothermal therapy of rheumatoid arthritis	21
Contents page	21
Therapeutic strategies of small molecules in the microbiota–gut–brain axis for alcohol use disorder	21
A FAIR-Decide framework for pharmaceutical R&D: FAIR data cost–benefit assessment	20